Nasal congestion

Sleep Specialist and Otolaryngologist, Julie Zweig, M.D., is Featured as a 2024 Top Patient Rated Doctor by Find Local Doctors

Retrieved on: 
Monday, March 11, 2024
Sleep, Sleep apnea, Hormone, Patient, Insomnia, Sleep medicine, University, MD, Ear, Suite, ENT, Patient satisfaction, Nasal congestion, Hearing loss, Kool-Aid, Medicine, Nose, Allergy, Multimedia, Physician, Hearing, Pharmaceutical industry

ALPHARETTA, Ga., March 11, 2024 /PRNewswire-PRWeb/ -- Dr. Julie Zweig, a renowned, board-certified ear nose and throat (ENT) and sleep medicine physician, has been recognized as a 2024 Top Patient Rated Otolaryngologist by Find Local Doctors. This prestigious title is awarded to practices that have received an exceptional number of five-star ratings and superior reviews from satisfied patients. Find Local Doctors, a trusted online directory, is dedicated to helping consumers find reputable physicians in their area. The recognition bestowed upon Dr. Zweig and her team is a testament to their commitment to providing top-notch care and achieving outstanding patient satisfaction.

Key Points: 
  • ALPHARETTA, Ga., March 11, 2024 /PRNewswire-PRWeb/ -- Dr. Julie Zweig, a renowned, board-certified ear nose and throat (ENT) and sleep medicine physician, has been recognized as a 2024 Top Patient Rated Otolaryngologist by Find Local Doctors.
  • Find Local Doctors , a trusted online directory, is dedicated to helping consumers find reputable physicians in their area.
  • Julie Zweig, MD Integrative Sleep & ENT is located at 2650 Holcomb Bridge Road, Suite 510 in Alpharetta, Georgia.
  • Dr. Julie Zweig, Julie Zweig, MD Integrative Sleep & ENT, 404-255-4080, [email protected] , https://juliezweigmd.com/
    View original content to download multimedia: https://www.prweb.com/releases/sleep-specialist-and-otolaryngologist-jul...

Aerin Medical Announces Positive Two-year Outcomes from the VATRAC Trial of VivAer®

Retrieved on: 
Thursday, February 8, 2024
Science, Other Science, Research, Medical Supplies, Health, Medical Devices, Clinical Trials, Other Health, NAO, ENT, Randomized controlled trial, Nasal congestion, Somnolence, Eastern Virginia Medical School, Nose, Exercise, Physician, Multimedia, Ear, Allergy, Patient, Network congestion, Pharmaceutical industry

Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial.

Key Points: 
  • Aerin Medical Inc. , a company dedicated to providing Ear, Nose and Throat (ENT) physicians with non-invasive solutions for the treatment of chronic nasal conditions, today announced that Rhinology Journal has published positive two-year outcomes from the VATRAC trial.
  • Previously published three-month results of the randomized controlled trial demonstrated that treatment with VivAer was safe and superior to a sham procedure.1
    This press release features multimedia.
  • View the full release here: https://www.businesswire.com/news/home/20240208997581/en/
    Two-year outcomes from the VATRAC trial published in Rhinology Journal confirm that treatment with VivAer® resulted in significant and lasting improvements in nasal obstruction symptoms.
  • This publication adds to a deep dossier of clinical evidence for VivAer, with three separate studies now confirming multi-year durability.

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 22-25 January 2024

Retrieved on: 
Sunday, February 4, 2024
Civil service commission, Pneumonia, Febrile neutropenia, Eli Lilly, Triprolidine, International, Bacteria, Schizophrenia, Myelopathy, Incidence, ALD, Cefepime, Allergic rhinitis, Nasal congestion, Neutrophil, Agency, COMP, Fever, HAP, EEIG, Headache, Static pressure, Medicine, Committee, Conditional, Spinal cord, Hospital-acquired pneumonia, PTC, Neutropenia, Public, CHMP, European, AMD, Patient, Diagnosis, Marketing, RCVS, European Commission, Brain, Disease, Infection, Inflammation, Male, PRES, PRAC, Pain, Pyelonephritis, Urinary tract infection, VAP, Ageing, EMA, Geographic atrophy, Adrenoleukodystrophy, Therapy, News, INN, Duchenne muscular dystrophy, Common, Fungal infection, Vaccine

Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.

Key Points: 
  • Three new medicines recommended for approvalEMA’s human medicines committee (CHMP) recommended three medicines for approval at its January 2024 meeting.The committee recommended…, Positive recommendations on new medicines, Exblifep International non-proprietary name (INN)cefepime / enmetazobactam Marketing-authorisation applicantAdvanz Pharma LimitedTherapeutic indicationTreatment of: 1)…, Ryzneuta INNefbemalenograstim alfaMarketing-authorisation applicantEvive Biotechnology Ireland LimitedTherapeutic indicationReduction in the duration of neutropenia and…, Positive recommendations on new generic medicines, Niapelf INNpaliperidoneMarketing-authorisation applicantNeuraxpharm Pharmaceuticals S.L.Therapeutic indicationTreatment of schizophreniaMore informationNiapelf: Pending…, Negative recommendations on new medicines, Nezglyal INNleriglitazoneMarketing-authorisation applicantMinoryx Therapeutics S.L.Therapeutic indicationTreatment of cerebral progression and myelopathy in male…, Syfovre INNpegcetacoplanMarketing-authorisation applicantApellis Netherlands B.V.Therapeutic indicationTreatment of geographic atrophy (GA) secondary to age-related…, Positive recommendations on extensions of indications, Abecma INNidecabtagene vicleucel Marketing-authorisation holderBristol-Myers Squibb Pharma EEIGMore informationAbecma: Pending EC decision, Prevenar 20 (previously Apexxnar) Common namepneumococcal polysaccharide conjugate vaccine (20-valent, adsorbed)Marketing-authorisation holderPfizer Europe MA EEIGMore…, Aspaveli INNpegcetacoplanMarketing-authorisation holderSwedish Orphan Biovitrum AB (publ)More informationAspaveli: Pending EC decision, Retsevmo INNselpercatinibMarketing-authorisation holderEli Lilly Nederland B.V.More informationRetsevmo: Pending EC decision, Outcome of re-examination of recommendation on non-renewal of Conditional Marketing Authorisation, Translarna INNataluren Marketing-authorisation holderPTC Therapeutics International LimitedNewsEMA confirms recommendation for non-renewal of authorisation of Duchenne…, Outcome of referral, Pseudoephedrine Marketing-authorisation holderVarious companiesMore informationPseudoephedrine-containing medicinal products, Re-examination of conclusion of referral, Synapse Labs Pvt.
  • Ltd. Marketing-authorisation holderVarious companiesMore informationSynapse

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Retrieved on: 
Tuesday, January 2, 2024
Medical Subject Headings, Diarrhea, Marketing, Agency, INN, Fever, Immune system, Fatigue, Constipation, Infection, Lymph, Hypotension, Virus, Bone marrow, Graft-versus-host disease, International, PTLD, Nasal congestion, Disease, Bone pain, Nausea, Language, Lymphoproliferative disorders, Cancer, Liver, Hyponatremia, Rash, Neutrophil, Appetite, Observation, European Medicines Agency, Transplant, Hypoxia, Select, Cell, Patient, Human, Safety, Dehydration, Anemia, Alkaline phosphatase, IIA, Epstein–Barr virus, Medical device

Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

Key Points: 


Human medicines European public assessment report (EPAR): Ebvallo, tabelecleucel, Date of authorisation: 16/12/2022, Revision: 3, Status: Authorised

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on: 
Monday, December 4, 2023
Nasal, Food, Risk, Johnson & Johnson, CFR, Phenylephrine, Petition, J&J, LLP, FDA, Ext, Court, Initiative, Find, Person, Nasal congestion, Register, News, Complaint, Pomerantz, KVUE, Prior, Prospectus, Safety, Defendant, District court, Action Replay, Pharmaceutical industry

NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points: 
  • NEW YORK, Dec. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Thursday, November 30, 2023
Suite, Nasal, Risk, Johnson & Johnson, Phenylephrine, FDA, GPM, Court, Nasal congestion, Register, News, KVUE, Prospectus, Defendant, Security (finance)

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Kenvue Inc. (KVUE)

Retrieved on: 
Wednesday, November 22, 2023
Suite, Nasal, Risk, Johnson & Johnson, Phenylephrine, FDA, GPM, Court, Nasal congestion, Register, News, KVUE, Prospectus, Defendant, Security (finance)

You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.

Key Points: 
  • You can also contact Charles H. Linehan, of GPM at 310-201-9150, Toll-Free at 888-773-9224, or via email at [email protected] to learn more about your rights.
  • In May 2023, Kenvue conducted an IPO, offering approximately 171,812,560 shares of Kenvue common stock to the investing public at $22.00 per share.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • Glancy Prongay & Murray LLP, Los Angeles

Kenvue Inc. Shareholders: Robbins LLP Reminds Shareholders that the Lead Plaintiff Deadline is Quickly Approaching and Encourages Shareholders to Reach out for Information

Retrieved on: 
Wednesday, November 22, 2023
Nasal, Food, Risk, Phenylephrine, LLP, FDA, Person, Nasal congestion, SAN, Register, KVUE, Prospectus

Kenvue Inc. operates as a consumer health company worldwide.

Key Points: 
  • Kenvue Inc. operates as a consumer health company worldwide.
  • For more information, submit a form , email Aaron Dumas, Jr., or give us a call at (800) 350-6003.
  • What Now: Similarly situated shareholders may be eligible to participate in the class action against Kenvue Inc. Shareholders who want to act as lead plaintiff for the class must file their motion for lead plaintiff by December 8, 2023.
  • A lead plaintiff is a representative party acting on behalf of other class members in directing the litigation.

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Kenvue, Inc. of Class Action Lawsuit and Upcoming Deadline – KVUE

Retrieved on: 
Tuesday, November 21, 2023
Nasal, Food, Risk, Johnson & Johnson, CFR, Phenylephrine, Petition, J&J, LLP, FDA, Ext, Court, Initiative, Find, Person, Nasal congestion, Register, News, Complaint, Pomerantz, KVUE, Prior, Prospectus, Safety, Defendant, District court, Action Replay, Pharmaceutical industry

NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.

Key Points: 
  • NEW YORK, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP announces that a class action lawsuit has been filed against Kenvue, Inc. (“Kenvue” or the “Company”) (NYSE: KVUE) and certain officers.
  • To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext.
  • Those who inquire by e-mail are encouraged to include their mailing address, telephone number, and the number of shares purchased.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions.

Singleton Schreiber: Johnson & Johnson, Proctor & Gamble, Wal-Mart Sued in Colorado Over Sale of Purported Decongestants

Retrieved on: 
Tuesday, December 26, 2023
Johnson & Johnson, Phenylephrine, The Case, Sale, FDA, Nasal congestion, Procter & Gamble, Federal court, Walmart, Case, Food and Drug Administration

DENVER, Dec. 26, 2023 /PRNewswire/ -- Singleton Schreiber filed a lawsuit in Colorado Federal Court against Johnson & Johnson, Proctor & Gamble, Wal-Mart alleging the market, distribution and sale of products containing phenylephrine mislead consumers.

Key Points: 
  • DENVER, Dec. 26, 2023 /PRNewswire/ -- Singleton Schreiber filed a lawsuit in Colorado Federal Court against Johnson & Johnson, Proctor & Gamble, Wal-Mart alleging the market, distribution and sale of products containing phenylephrine mislead consumers.
  • According to the complaint, these corporations made, sold, advertised and marketed products such as Tylenol Cold & Flu, Vicks Dayquil & Nyquil, among many others.
  • The Federal Drug Administration (FDA) released a study on September 12, 2023 and announced publicly that phenylephrine is ineffective.
  • The Case is Rethea Morris, Robert Haid v. Johnson & Johnson, Proctor & Gamble, Wal-Mart, USDC District of Colorado, Case No.